Thursday, June 30, 2022

InflaRx Update For Vilobelimab In Skin Disorder, COVID-19

›
  InflaRx N.V.   IFRX +2.84% + Free Alerts   provided a development update  for its monoclonal anti-C5a antibody, vilobelimab, in pyoderma g...

Genmab Applies to FDA on Large B-Cell Lymphoma Trials

›
  Genmab A/S  (Nasdaq: GMAB)  today announced its intent to submit a biologics license application (BLA) to the U.S. Food and Drug Administr...

Blueprint Draws Combined $1.25B Investment in Tough Market

›
  Blueprint Medicines   announced   strategic financing collaborations with Sixth Street and Royalty Pharma totaling up to $1.25 billion. Th...

Aura Biosciences Gets Fast Track Designation for AU-011 Bladder Cancer Treatment

›
  Aura Biosciences Inc. said the U.S. Food and Drug Administration has granted Fast Track designation for belzupacap sarotalocan AU-011 for ...

Sanofi's Phase 3 Trials of Multiple Sclerosis Drug Partially Paused by FDA

›
  Sanofi SA said Thursday that the Food and Drug Administration has paused some U.S.-based Phase 3 trials of drug tolebrutinib for treatment...

UHS: UPDATE ON 2Q OPERATING RESULTS, REVISES 2022 FULL YEAR EARNINGS GUIDANCE

›
  Universal Health Services, Inc. (NYSE: UHS) announced today that, due to a significant shortfall in operating results experienced during A...

Nurix Application Cleared for More Indications

›
  NX-1607 is being evaluated in multiple immuno-oncology indications, including a range of solid tumor types Phase 1 clinical trial now enro...